Nonivamide/Nicoboxil Ointment in Acute Low Back Pain

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01708915
First received: October 16, 2012
Last updated: July 10, 2013
Last verified: July 2013

October 16, 2012
July 10, 2013
October 2012
April 2013   (final data collection date for primary outcome measure)
pain intensity differences (PID) from pre-dose baseline 8hours after first application [ Time Frame: 8 hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01708915 on ClinicalTrials.gov Archive Site
  • pain intensity difference (PID) from pre-dose baseline 4 hours after first application [ Time Frame: 4 hours ] [ Designated as safety issue: No ]
  • difference of average pain intensity from pre-dose baseline on the last individual treatment day [ Time Frame: 1 - 5 days ] [ Designated as safety issue: No ]
  • patient assessment of efficacy on the last individual treatment day [ Time Frame: 1 day ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Nonivamide/Nicoboxil Ointment in Acute Low Back Pain
A Multi-centre, Double-blind, Randomised, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Topically Applied Hyperemisation-inducing Ointment (2cm Ointment Line Per Application; up to 3 Times Daily for up to 4 Days) Containing 2.5% Nicoboxil/0.4% Nonivamide Versus 2.5% Nicoboxil, 0.4% Nonivamide and Placebo in Patients 18 to 65 Years of Age With Acute Low Back Pain

The aim of this study is to assess the efficacy and tolerability of Nicoboxil/Nonivamide ointment in comparison to Nicoboxil, Nonivamide, and placebo ointments for the treatment of acute low back pain to obtain a market authorization in Germany for this indication.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Low Back Pain
  • Drug: nicoboxil
    2cm ointment line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
  • Drug: placebo matching nonivamide + nicoboxil
    2cm ointment line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
  • Drug: nonivamide + nicoboxil (Finalgon)
    2cm ointment line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
  • Drug: nonivamide
    2cm ointment line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
  • Active Comparator: nonivamide + nicoboxil (Finalgon)
    2cm ointment line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
    Intervention: Drug: nonivamide + nicoboxil (Finalgon)
  • Active Comparator: nonivamide
    2cm ointment line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
    Intervention: Drug: nonivamide
  • Active Comparator: nicoboxil
    2cm ointment line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
    Intervention: Drug: nicoboxil
  • Placebo Comparator: placebo
    2cm ointment line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
    Intervention: Drug: placebo matching nonivamide + nicoboxil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
806
April 2013
April 2013   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Patients must sign and date an Informed Consent consistent with International Conference on Hermonisation (ICH)/Good Clinical Practice (GCP) guidelines and local regulation prior to participation in the trial.
  • Patients must agree to cooperate with all trial evaluations and perform all required tasks.
  • Acute low back pain for more than 2 days and less than 21 days (= 3 weeks)
  • Male or female patients aged 18 to 65 years
  • Low back pain rating >5 on a 0-10 numerical rating scale (NRS).
  • Female patients of childbearing potential may participate only in case of
  • availability of a negative urine pregnancy test and
  • a confirmed menstrual period prior to study entry
  • Women of childbearing potential using a highly effective method of birth control. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1 % per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, appropriate intrauterine devices, sexual abstinence or vasectomised partner. Barrier methods of contraception (e.g. condom, diaphragma or occlusive cap) are accepted if used in combination with spermicides (e.g. foam, gel). Female patients will be considered being of childbearing potential unless surgically sterilised by bilateral tubal ligation/salpingectomy or hysterectomy or post-menopausal for at least one year.

Exclusion criteria:

  • Multilocular pain or panalgesia
  • History of more than three low back pain episodes in the last six months
  • Abnormal findings in at least one of the following assessments: Achilles tendon reflex, patella reflex, heel walking, toe walking, cutaneous sensitivity of the legs (including gluteal region), paresis tests in supine position upon dorsiflexion, plantarflexion, hip flexion, knee extension
  • Bladder and/or rectum dysfunction
  • Acute low back pain due to vertebral collapse or neoplastic, inflammatory (ankylosing spondylitis), traumatic, or infective origins
  • Any condition, disease or concomitant treatment that in the judgement of the Investigator will affect the subject's ability to participate in the clinical trial or which will influence the test methodology used
  • Negative experience in the past with heat treatment for muscle complaints (e. g. hot water bottle, heat pads, hyperemisation-inducing topical creams, ointments or patches)
  • History of treatment of back pain with centrally acting analgesics (e. g. opioids) and muscle relaxants
  • Surgery due to back pain or rehabilitation due to back pain in the last 12 months
  • Spinal injection back pain treatment within 6 months prior to enrollment
  • Intake of antidepressant/antipsychotic medication within 4 weeks prior to enrollment
  • Treatment of the recent low back pain period with oral analgesics for more than 4 consecutive days
  • Locally applied medication to the back within 48 hours prior to enrollment (topical treatments, injections)
  • Administration of other analgesics within 24 h prior to enrollment (exception: acetyl salicylic acid (ASS) up to 100 mg/daily for anti platelet-aggregation therapy)
  • Non-pharmacological low back pain treatment (physiotherapy, heat treatment (e.g. hot water bottle, heat patch, or massages) within 12 h prior to enrollment
  • Participation in an investigational drug or device trial within 4 weeks prior to enrollment
  • Hypersensitivity to Nicoboxil, Nonivamide, or paracetamol
  • Known hypersensitivity to any other ingredient, especially to sorbic acid/sorbate, to citronella oil containing e.g. the fragrance compounds geraniol, citronellol and citronellal, or to relevant flowers containing these compounds such as geranium, lavender, jasmine or rose. For patients with known hypersensitivity to perfumes or known type IV hypersensitivity to fragrance-mix I, the application of the investigational product should be performed only with particular caution.
  • Skin lesions (e. g., rash, dermatitis, bruising, laceration) in the back region
  • Drug dependence and/or alcohol abuse
  • Severe hepatocellular insufficiency
  • Patients who are pregnant or breast-feeding
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01708915
69.52, 2011-003890-27
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP